Abstract
Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin.
Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020.
Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors.
Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.
Keywords: Concentrated insulin U-500, pharmacokinetics, pharmacodynamics, efficacy, safety, insulin.
Current Diabetes Reviews
Title:Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements
Volume: 17 Issue: 1
Author(s): Nasser Mikhail*
Affiliation:
- Department of Medicine, Endocrinology Division, Olive View-UCLA Medical Center, 14445 Olive View Dr. Sylmar, 91342,United States
Keywords: Concentrated insulin U-500, pharmacokinetics, pharmacodynamics, efficacy, safety, insulin.
Abstract:
Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin.
Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020.
Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors.
Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.
Export Options
About this article
Cite this article as:
Mikhail Nasser *, Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements, Current Diabetes Reviews 2021; 17 (1) . https://dx.doi.org/10.2174/1573399816666200408084614
DOI https://dx.doi.org/10.2174/1573399816666200408084614 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Cell Immunity in Cardiovascular and Cerebrovascular Diseases)
Current Immunology Reviews (Discontinued) Subject Index To Volume 2
Current Respiratory Medicine Reviews The Ligand Nanoparticle Conjugation Approach for Targeted Cancer Therapy
Current Drug Metabolism Tissue Plasminogen Activator (tPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Editorial
Current Nutrition & Food Science Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets The Zinc Metallopeptidase Family: New Faces, New Functions
Protein & Peptide Letters Editorial (Thematic Issue: AMPK: New Frontiers in Human Diseases)
Current Drug Targets The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Development and Evaluation of Nateglinide Loaded Polycaprolactone Nanoparticles
Micro and Nanosystems Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Inhibitors of HMG-CoA Reductase: Current and Future Prospects
Mini-Reviews in Medicinal Chemistry Transdermal Innovations in Diabetes Management
Current Diabetes Reviews Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Approaches for the Cure of Type 1 Diabetes by Cellular and Gene Therapy
Current Gene Therapy Regulation of Mitochondrial Biogenesis in Metabolic Syndrome
Current Drug Targets The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Insulin-like Effects of Mt. Fuji Subsoil Water which Conta ins Vanadium on Cultured Cells: Insight from Japan
Current Traditional Medicine